About   Help   FAQ
Mammalian Phenotype Ontology Annotations
Query Results - Summary
Symbol
Name
ID 		Pten
phosphatase and tensin homolog
MGI:109583
301 phenotypes from multigenic genotypes
Export: Excel File
Allelic Composition
Genetic Background		 Annotated Term Reference
\Akt1tm1Nhy/\Akt1+
\Akt2tm1Rsg/\Akt2tm1Rsg
\Ptentm1Ppp/\Pten+
involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * DBA/1LacJ 		enlarged pancreatic islets J:149156
impaired glucose tolerance J:149156
increased circulating insulin level J:149156
\Akt2tm1.1Mbb/\Akt2tm1.1Mbb
\Ptentm1Hwu/\Ptentm1Hwu
\Speer6-ps1Tg(Alb-cre)21Mgn/\Speer6-ps1+
involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6 * DBA 		abnormal liver morphology J:218587
decreased susceptibility to hepatic steatosis J:218587
hyperglycemia J:160759
impaired glucose tolerance J:160759
increased tumor latency J:218587
normal liver/biliary system phenotype J:160759
\Akt2tm1Rsg/\Akt2tm1Rsg
\Ptentm1Ppp/\Pten+
involves: 129S1/Sv * C57BL/6 * DBA/1LacJ 		decreased circulating insulin level J:149156
impaired glucose tolerance J:149156
\Albtm1(cre/ERT2)Mtz/\Alb+
\Krastm4Tyj/\Kras+
\Ptentm2Mak/\Ptentm2Mak
involves: 129P2/OlaHsd * 129S2/SvPas * 129S4/SvJae 		increased cholangiocarcinoma incidence J:254370
increased hepatocellular carcinoma incidence J:254370
\Amhr2tm3(cre)Bhr/\Amhr2+
\Ctnnb1tm1Mmt/\Ctnnb1+
\Ptentm1Hwu/\Ptentm1Hwu
involves: 129S4/SvJae * 129S7/SvEvBrd * 129X1/SvJ 		anemia J:142150
decreased hematocrit J:142150
extramedullary hematopoiesis J:142150
increased granulosa cell tumor incidence J:149060
increased metastatic potential J:142150, J:149060
increased ovary tumor incidence J:142150
increased testis tumor incidence J:149060
premature death J:142150
pulmonary embolism J:142150
seminiferous tubule degeneration J:149060
\Amhr2tm3(cre)Bhr/\Amhr2+
\Ctnnb1tm1Mmt/\Ctnnb1+
\Ptentm1Hwu/\Ptentm1Hwu
involves: 129S4/SvJae * 129S7/SvEvBrd * 129X1/SvJ * C57BL/6 		increased granulosa cell tumor incidence J:186144
increased testis tumor incidence J:186144
\ApcMin/\Apc+
\Ptentm1Hwu/\Ptentm1Hwu
\Tg(Vil1-cre)997Gum/0
involves: 129S4/SvJae * BALB/c * C57BL/6J * SJL 		increased intestinal adenoma incidence J:150553
intestine polyps J:150553
premature death J:150553
\Apctm1Tno/\Apc+
\Ptentm2Mak/\Ptentm2Mak
\Tg(Cyp1a1-cre/ERT)1Dwi/0
involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6 * CBA 		abnormal small intestine morphology J:143082
increased intestinal adenocarcinoma incidence J:143082
peritoneal inflammation J:143082
premature death J:143082
\Apctm1Tno/\Apctm1Tno
\Ptentm1Hwu/\Ptentm1Hwu
\Tg(Cyp1a1-cre/ERT)1Dwi/0
involves: 129S4/SvJae * C57BL/6 * CBA 		abnormal urinary bladder urothelium morphology J:164579
\Apctm1Tno/\Apctm1Tno
\Ptentm2Mak/\Ptentm2Mak
involves: 129P2/OlaHsd * 129S4/SvJae 		decreased tumor-free survival time J:120955
hemorrhagic ascites J:120955
increased ovarian carcinoma incidence J:120955
\Artm1Verh/Y
\Ptentm1Hwu/\Ptentm1Hwu
\Tg(Pbsn-cre)4Prb/0
involves: 129S1/Sv * 129S4/SvJae * 129X1/SvJ * C57BL/6 * DBA/2 		increased prostate gland adenocarcinoma incidence J:172730
\Bcl2l11tm1.1Ast/\Bcl2l11+
\Ptentm1Hwu/\Pten+
\Tg(CD2-icre)4Kio/0
involves: 129S1/Sv * 129S4/SvJae * C57BL/10 * CBA/Ca 		abnormal T cell number J:133215
increased germinal center B cell number J:133215
\Braftm1Mmcm/\Braf+
\Ptentm1Mro/\Ptentm1Mro
\Tg(Tyr-cre/ERT2)1Lru/0
B6.Cg-Braftm1Mmcm Tg(Tyr-cre/ERT2)1Lru Ptentm1Mro 		decreased tumor-free survival time J:188523
increased cutaneous melanoma incidence J:188523
premature death J:188523
spontaneous skin ulceration J:188523
\Braftm1Mmcm/\Braf+
\Ptentm2.1Ppp/\Pten+
\Tg(Tyr-cre/ERT2)13Bos/0
involves: 129P2/OlaHsd * 129S1/Sv * FVB 		abnormal melanocyte morphology J:151023
increased cutaneous melanoma incidence J:151023
\Braftm1Mmcm/\Braf+
\Ptentm2.1Ppp/\Ptentm2.1Ppp
\Tg(Tyr-cre/ERT2)13Bos/0
involves: 129P2/OlaHsd * 129S1/Sv * FVB 		increased cutaneous melanoma incidence J:151023
increased metastatic potential J:151023
\Braftm1Mmcm/\Braf+
\Ptentm1Rdp/\Ptentm1Rdp
\Tg(Tyr-cre/ERT2)13Bos/0
involves: 129P2/OlaHsd * 129S6/SvEvTac * C57BL/6 * FVB/N 		increased cutaneous melanoma incidence J:151023
increased metastatic potential J:151023
\Braftm1Mmcm/\Braftm1Mmcm
\Nkx3-1tm4(cre/ERT2)Mms/\Nkx3-1+
\Ptentm1Hwu/\Pten+
involves: 129P2/OlaHsd * 129S4/SvJae * 129S6/SvEvTac * C57BL/6 		increased metastatic potential J:191327
increased prostate gland adenocarcinoma incidence J:191327
increased prostate gland tumor incidence J:191327
increased prostate intraepithelial neoplasia incidence J:191327
premature death J:191327
\Calcatm1.1(cre/ERT2)Ptch/\Calca+
\Trp53tm1Brn/\Trp53tm1Brn
\Rb1tm2Brn/\Rb1tm2Brn
\Ptentm1Hwu/\Ptentm1Hwu
involves: 129 * 129P2/OlaHsd * 129S4/SvJae * BALB/c * FVB/N 		abnormal pulmonary neuroendocrine body morphology J:190366
increased lung small cell carcinoma incidence J:190366
increased metastatic potential J:190366
increased thyroid tumor incidence J:190366
postnatal lethality J:190366
\Cd19tm1(cre)Cgn/\Cd19+
\Ptentm1Hwu/\Ptentm1Hwu
\Tg(IghelMD4)4Ccg/0
\Tg(ML5sHEL)5Ccg/0
involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6 		abnormal peripheral B cell anergy J:155314
\Cd19tm1(cre)Cgn/\Cd19+
\Inpp5dtm1Rav/\Inpp5dtm1Rav
\Ptentm1Hwu/\Ptentm1Hwu
involves: 129P2/OlaHsd * 129S4/SvJae 		abnormal B cell morphology J:166155
abnormal B cell physiology J:166155
abnormal coat appearance J:166155
abnormal myeloid leukocyte morphology J:166155
decreased B cell number J:166155
enlarged spleen J:166155
hunched posture J:166155
increased B cell number J:166155
increased B cell proliferation J:166155
increased follicular lymphoma incidence J:166155
increased lymphoma incidence J:166155
increased malignant tumor incidence J:166155
increased plasmacytoma incidence J:166155
increased spleen white pulp amount J:166155
increased splenic marginal zone lymphoma incidence J:166155
lethargy J:166155
premature death J:166155
weight loss J:166155
\Cdkn1atm1Tyj/\Cdkn1atm1Tyj
\Ptentm1Hwu/\Ptentm1Hwu
\Tg(Fabp1-cre)1Jig/0
involves: 129S2/SvPas * 129S4/SvJae * FVB/N 		abnormal urinary bladder urothelium morphology J:106662
increased urinary bladder carcinoma incidence J:106662
\Cdkn1btm1Ako/\Cdkn1b+
\Ptentm2.1Ppp/\Ptentm2.1Ppp
\Tg(TPO-cre)1Shk/0
129S1.Cg-Cdkn1btm1Ako Tg(TPO-cre)1Shk Ptentm2.1Ppp 		increased thyroid adenoma incidence J:165293
increased thyroid carcinoma incidence J:165293
premature death J:165293
\Cdkn1btm1Ako/\Cdkn1btm1Ako
\Ptentm2.1Ppp/\Ptentm2.1Ppp
\Tg(TPO-cre)1Shk/0
129S1.Cg-Cdkn1btm1Ako Tg(TPO-cre)1Shk Ptentm2.1Ppp 		premature death J:165293
respiratory distress J:165293
thyroid gland hyperplasia J:165293
\Cdkn2atm1Rdp/\Cdkn2atm1Rdp
\Col1a1tm1(CAG-EGFR)Char/\Col1a1tm1(CAG-EGFR)Char
\Ptentm1Hwu/\Ptentm1Hwu
involves: 129/Sv * 129S4/SvJae * C57BL/6 * SJL 		decreased tumor-free survival time J:146494
increased glioblastoma incidence J:146494
\Cdkn2atm1Rdp/\Cdkn2atm1Rdp
\Col1a1tm1(CAG-EGFR)Char/\Col1a1tm2(CAG-EGFR*)Char
\Ptentm1Hwu/\Ptentm1Hwu
involves: 129/Sv * 129S4/SvJae * C57BL/6 * SJL 		decreased tumor-free survival time J:146494
increased glioblastoma incidence J:146494
\Cdkn2atm1Rdp/\Cdkn2atm1Rdp
\Col1a1tm2(CAG-EGFR*)Char/\Col1a1tm2(CAG-EGFR*)Char
\Ptentm1Hwu/\Ptentm1Hwu
involves: 129/Sv * 129S4/SvJae * C57BL/6 * SJL 		decreased tumor-free survival time J:146494
increased glioblastoma incidence J:146494
\Cdkn2atm1Rdp/\Cdkn2atm1Rdp
\Ctnnb1tm1Mmt/\Ctnnb1tm1Mmt
\Ptentm1Rps/\Ptentm1Rps
\Tg(Tyr-cre/ERT2)13Bos/0
involves: 129/Sv * C57BL/6J * FVB * SJL 		increased melanoma incidence J:155731
\Cdkn2atm1Rdp/\Cdkn2atm1Rdp
\Gt(ROSA)26Sortm1(rtTA,EGFP)Nagy/\Gt(ROSA)26Sor+
\Ptentm1Rdp/\Ptentm1Rdp
\Tg(tetO-BRAF*V600E)29Lc/0
\Tg(Tyr-cre/ERT2)13Bos/0
involves: 129/Sv * C57BL/6J * FVB * SJL 		increased melanoma incidence J:221902
\Cdkn2atm1Rdp/\Cdkn2atm1Rdp
\Ptentm1Rps/\Ptentm1Rps
\Tg(Tyr-cre/ERT2)13Bos/0
involves: 129/Sv * 129S1/Sv * C57BL/6J * FVB/N * SJL 		increased melanoma incidence J:155731
\Coro1ctm1c(KOMP)Wtsi/\Coro1ctm1c(KOMP)Wtsi
\Ptentm2Mak/\Ptentm2Mak
\Trp53tm1Brn/\Trp53tm1Brn
\Tg(GFAP-cre/Esr1*,-lacZ)ASbk/0
involves: 129P2/OlaHsd * C57BL/6N * FVB/NJ 		increased glioblastoma incidence J:290447
premature death J:290447
\Ctnnb1tm1Mmt/\Ctnnb1+
\Ptentm1Hwu/\Ptentm1Hwu
\Tg(CYP19A1-cre)1Jri/0
involves: 129S4/SvJae * 129X1/SvJ * C57BL/6 		decreased circulating estradiol level J:186144
decreased circulating progesterone level J:186144
decreased granulosa cell apoptosis J:186144
decreased tumor-free survival time J:186144
impaired granulosa cell differentiation J:186144
increased circulating follicle stimulating hormone level J:186144
increased circulating luteinizing hormone level J:186144
increased granulosa cell proliferation J:186144
increased granulosa cell tumor incidence J:186144
increased ovary tumor incidence J:186144
\Ctnnb1tm1Mmt/\Ctnnb1+
\Ptentm1Hwu/\Ptentm1Hwu
\Tg(Upk2-cre)6Xrw/0
involves: 129S4/SvJae * 129X1/SvJ * FVB/N 		increased urinary bladder carcinoma incidence J:164579
premature death J:164579
\Ctnnb1tm1Mmt/\Ctnnb1tm1Mmt
\Ptentm1Hwu/\Ptentm1Hwu
\Tg(Upk2-cre)6Xrw/0
involves: 129S4/SvJae * 129X1/SvJ * FVB/N 		increased urinary bladder carcinoma incidence J:164579
premature death J:164579
\Ctnnb1tm2Kem/\Ctnnb1+
\Ptentm1Hwu/\Ptentm1Hwu
\Tg(Cdh5-cre)7Mlia/0
involves: 129S1/Sv * 129S4/SvJae * 129X1/SvJ * BALB/c * C57BL/6 * FVB/N 		abnormal blood vessel morphology J:135172
abnormal definitive hematopoiesis J:135172
premature death J:135172
\Ctnnb1tm2Kem/\Ctnnb1tm2Kem
\Ptentm1Hwu/\Ptentm1Hwu
\Tg(Cdh5-cre)7Mlia/0
involves: 129S1/Sv * 129S4/SvJae * 129X1/SvJ * BALB/c * C57BL/6 * FVB/N 		embryonic lethality, complete penetrance J:135172
\Del(16Tmprss2-Erg)1Sho/\Del(16Tmprss2-Erg)1Sho
\Ptentm1.1Hwu/\Pten+
involves: 129S4/SvJae * C57BL/6 * DBA/2 		increased prostate intraepithelial neoplasia incidence J:212219
\Dicer1tm1Tara/\Dicer1tm1Tara
\Ptentm1Hwu/\Ptentm1Hwu
\Amhr2tm3(cre)Bhr/\Amhr2+
involves: 129P2/OlaHsd * 129S4/SvJae * 129S7/SvEvBrd 		abnormal oviduct morphology J:182161
ascites J:182161
increased carcinoma incidence J:182161
increased metastatic potential J:182161
increased ovarian carcinoma incidence J:182161
premature death J:182161
\Dicer1tm1Tara/\Dicer1tm1Tara
\Ptentm1Hwu/\Ptentm1Hwu
\Trp53tm2Tyj/\Trp53+
\Amhr2tm3(cre)Bhr/\Amhr2+
involves: 129P2/OlaHsd * 129S4/SvJae * 129S7/SvEvBrd 		ascites J:222579
increased carcinoma incidence J:222579
increased metastatic potential J:222579
increased ovarian carcinoma incidence J:222579
premature death J:222579
\Eif2ak3tm1.2Drc/\Eif2ak3tm1.2Drc
\Ptentm1Hwu/\Ptentm1Hwu
\Tg(CAG-MYC,-GFP*)#Rugg/0
\Tg(Pbsn-cre)4Prb/0
involves: 129S4/SvJae * 129S6/SvEvTac * C57BL/6 * C57BL/6J * DBA/2 		decreased prostate gland tumor incidence J:261540
\Eif4etm1.1Lfur/\Eif4etm1.1Lfur
\Ptentm2.1Ppp/\Ptentm2.1Ppp
\Tg(Pbsn-cre)4Prb/0
involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * DBA/2 		decreased tumor incidence J:163589
\Erbb2tm8(Erbb2)Mul/\Erbb2+
\Ptentm1Hwu/\Pten+
\Tg(MMTV-cre)7Mul/0
involves: 129S1/Sv * 129S4/SvJae * 129X1/SvJ * FVB/N 		increased mammary gland tumor incidence J:133305
increased metastatic potential J:133305
\Erbb2tm8(Erbb2)Mul/\Erbb2+
\Ptentm1Hwu/\Ptentm1Hwu
\Tg(MMTV-cre)7Mul/0
involves: 129S1/Sv * 129S4/SvJae * 129X1/SvJ * FVB/N 		increased mammary gland tumor incidence J:133305
\Ergtm1.1Sho/\Ergtm1.1Sho
\Ptentm1Hwu/\Ptentm1Hwu
\Tmprss2tm3Sho/\Tmprss2tm3Sho
\Tg(Pbsn-cre)4Prb/0
involves: 129S4/SvJae * C57BL/6 * DBA/2 		increased prostate gland adenocarcinoma incidence J:212219
normal mortality/aging J:212219
\Errfi1tm1Jwj/\Errfi1tm1Jwj
\Pgrtm2(cre)Lyd/\Pgr+
\Ptentm1Hwu/\Ptentm1Hwu
involves: 129S1/Sv * 129S4/SvJae * 129X1/SvJ 		abnormal endometrium morphology J:162027
endometrium hyperplasia J:162027
increased endometrial carcinoma incidence J:162027
increased metastatic potential J:162027
increased uterus weight J:162027
premature death J:162027
\Ets2tm1Rgo/\Ets2tm5.1Rgo
\Ptentm1.1Mwst/\Ptentm1.1Mwst
\Tg(S100a4-cre)1Gle/0
involves: 129S2/SvPas * FVB/N 		abnormal tumor morphology J:153747
decreased mammary gland tumor incidence J:153747
increased mammary gland tumor incidence J:153747
\Fastm1Ach/\Fastm1Ach
\Krastm4Tyj/\Kras+
\Ptentm1Hwu/\Ptentm1Hwu
involves: 129S4/SvJae 		decreased ovarian tumor incidence J:161953
\Foxo1tm1Rdp/\Foxo1tm1.1Rdp
\Foxo3tm1Rdp/\Foxo3tm1.1Rdp
\Ptentm1Hwu/\Ptentm1Hwu
\Tg(CYP19A1-cre)1Jri/0
involves: 129S4/SvJae * 129S6/SvEvTac 		abnormal circulating hormone level J:232961
decreased circulating luteinizing hormone level J:232961
increased granulosa cell tumor incidence J:232961
suppressed circulating follicle stimulating hormone level J:232961
\Grb2tm1Paw/\Grb2+
\Ptentm1Mak/\Pten+
involves: 129P2/OlaHsd * 129S1/Sv * 129X1/SvJ * C57BL/6 		increased adrenal gland tumor incidence J:93530
increased endometrial carcinoma incidence J:93530
increased lymphoma incidence J:93530
increased tumor incidence J:93530
normal mortality/aging J:93530
\Grb2tm1Paw/\Grb2+
\Ptentm2Mak/\Ptentm2Mak
\Tg(Lck-cre)548Jxm/0
involves: 129P2/OlaHsd * C57BL/6 * CBA 		increased T cell derived lymphoma incidence J:93530
\Grhl3tm1Jane/\Grhl3+
\Ptentm1Mak/\Pten+
involves: 129P2/OlaHsd * 129S1/Sv 		increased skin papilloma incidence J:178952
increased skin squamous cell carcinoma incidence J:178952
\Gt(ROSA)26Sortm1(CAG-Bmi1,-EGFP)Nki/\Gt(ROSA)26Sor+
\Ptentm1Mro/\Pten+
\Tg(Pbsn-cre)4Prb/0
involves: 129P2/OlaHsd * C57BL/6 * DBA/2 * FVB/N 		increased prostate gland adenocarcinoma incidence J:184533
increased prostate intraepithelial neoplasia incidence J:184533
urinary bladder obstruction J:184533
\Gt(ROSA)26Sortm1(CAG-Errfi1)Jwj/?
\Pgrtm2(cre)Lyd/\Pgr+
\Ptentm1Hwu/\Ptentm1Hwu
involves: 129S1/Sv * 129S4/SvJae * 129X1/SvJ * C57BL/6 		abnormal uterus physiology J:218222
endometrium hyperplasia J:218222
increased papilloma incidence J:218222
increased uterus weight J:218222
premature death J:218222
\Gt(ROSA)26Sortm1(CAG-MYCN,-luc)Jhsc/\Gt(ROSA)26Sor+
\Ptentm2.1Ppp/\Ptentm2.1Ppp
\Rb1tm2Brn/\Rb1+
\Tg(Pbsn-cre)4Prb/0
involves: 129 * 129S1/Sv * 129S6/SvEvTac * C57BL/6 * DBA/2 		increased prostate gland tumor incidence J:307910
premature death J:307910
\Gt(ROSA)26Sortm1(CAG-MYCN,-luc)Jhsc/\Gt(ROSA)26Sor+
\Ptentm2.1Ppp/\Ptentm2.1Ppp
\Rb1tm2Brn/\Rb1tm2Brn
\Tg(Pbsn-cre)4Prb/0
involves: 129 * 129S1/Sv * 129S6/SvEvTac * C57BL/6 * DBA/2 		increased metastatic potential J:307910
increased prostate gland tumor incidence J:307910
premature death J:307910
\Gt(ROSA)26Sortm1(CAG-MYCN,-luc)Jhsc/\Gt(ROSA)26Sor+
\Ptentm2.1Ppp/\Ptentm2.1Ppp
\Tg(Pbsn-cre)4Prb/0
involves: 129 * 129S1/Sv * 129S6/SvEvTac * C57BL/6 * DBA/2 		increased prostate intraepithelial neoplasia incidence J:307910
premature death J:307910
\Gt(ROSA)26Sortm1(H1/tetO-RNAi:Pdpk1)Mrl/\Gt(ROSA)26Sor+
\Ptentm1Hwu/\Ptentm1Hwu
\Tg(Pbsn-cre)4Prb/0
involves: 129S4/SvJae * C57BL/6 * DBA/2 		abnormal prostate gland physiology J:170965
enlarged prostate gland anterior lobe J:170965
increased prostate gland tumor incidence J:170965
increased prostate gland weight J:170965
prostate gland hyperplasia J:170965
\Gt(ROSA)26Sortm1(H1/tetO-RNAi:Pdpk1)Mrl/\Gt(ROSA)26Sor+
\Ptentm1.1Hwu/\Pten+
involves: 129S4/SvJae * C57BL/6NTac 		increased lymphoma incidence J:170965
increased thyroid adenoma incidence J:170965
\Gt(ROSA)26Sortm1(H1/tetO-RNAi:Pdpk1)Mrl/\Gt(ROSA)26Sortm9(cre/ESR1)Arte
\Ptentm1Hwu/\Ptentm1Hwu
involves: 129S4/SvJae * C57BL/6 		decreased B cell number J:170965
disheveled coat J:170965
enlarged lymph nodes J:170965
enlarged spleen J:170965
hunched posture J:170965
increased acute lymphoblastic leukemia incidence J:170965
increased memory B cell number J:170965
increased spleen weight J:170965
premature death J:170965
weight loss J:170965
\Gt(ROSA)26Sortm1(JAG1)Xin/\Gt(ROSA)26Sor+
\Ptentm1Hwu/\Ptentm1Hwu
\Tg(Pbsn-cre)20Fwan/?
involves: 129S4/SvJae * C57BL/6 * FVB/NCrl 		abnormal prostate gland morphology J:238768
increased prostate gland adenocarcinoma incidence J:238768
increased prostate intraepithelial neoplasia incidence J:238768
\Gt(ROSA)26Sortm1(Notch1)Dam/\Gt(ROSA)26Sor+
\Ptentm1Hwu/\Ptentm1Hwu
\Tg(Adipoq-cre)1Evdr/0
involves: 129S4/SvJae * 129S4/SvJaeSor * C57BL/6J * FVB/NJ 		abnormal brown adipose tissue morphology J:237232
normal homeostasis/metabolism phenotype J:237232
increased liposarcoma incidence J:237232
lipodystrophy J:237232
\Gt(ROSA)26Sortm1(SPOP*F133V)Mrbn/\Gt(ROSA)26Sor+
\Ptentm2.1Ppp/\Pten+
\Tg(Pbsn-cre)4Prb/0
involves: 129S1/Sv * C57BL/6 * DBA/2 		increased prostate gland adenocarcinoma incidence J:239660
increased prostate intraepithelial neoplasia incidence J:239660
\Gt(ROSA)26Sortm1(SPOP*F133V)Mrbn/\Gt(ROSA)26Sor+
\Ptentm2.1Ppp/\Ptentm2.1Ppp
\Tg(Pbsn-cre)4Prb/0
involves: 129S1/Sv * C57BL/6 * DBA/2 		increased prostate gland adenocarcinoma incidence J:239660
\Gt(ROSA)26Sortm1(TMPRSS2/ERG)Key/\Gt(ROSA)26Sortm1(TMPRSS2/ERG)Key
\Ptentm2.1Ppp/\Ptentm2.1Ppp
\Tg(Pbsn-cre)4Prb/0
involves: 129S1/Sv * C57BL/6 * DBA/2 		abnormal prostate gland physiology J:200002
distended abdomen J:200002
enlarged prostate gland J:200002
increased prostate gland adenocarcinoma incidence J:200002
increased prostate intraepithelial neoplasia incidence J:200002
penis prolapse J:200002
premature death J:200002
\Gt(ROSA)26Sortm1Sor/\Gt(ROSA)26Sortm1Sor
\Ptentm1Mro/\Ptentm1Mro
\Rb1tm2Brn/\Rb1tm2Brn
involves: 129 * 129S4/SvJaeSor * C57BL/6 * FVB 		normal neoplasm J:204385
\Gt(ROSA)26Sortm1Sor/\Gt(ROSA)26Sortm1Sor
\Ptentm1Mro/\Ptentm1Mro
\Rb1tm2Brn/\Rb1tm2Brn
\Trp53tm1Brn/\Trp53tm1Brn
involves: 129 * 129P2/OlaHsd * 129S4/SvJaeSor * C57BL/6 * FVB/N 		increased nervous system tumor incidence J:204385
\Gt(ROSA)26Sortm1Sor/\Gt(ROSA)26Sortm1Sor
\Ptentm1Mro/\Ptentm1Mro
\Slc1a3tm1(cre/ERT2)Mgoe/\Slc1a3+
\Trp53tm1Brn/\Trp53tm1Brn
involves: 129P2/OlaHsd * 129S2/SvPas * 129S4/SvJaeSor 		increased astrocytoma incidence J:229481
increased glioma incidence J:229481
increased oligodendroglioma incidence J:229481
\Gt(ROSA)26Sortm1Sor/\Gt(ROSA)26Sortm1Sor
\Ptentm1Mro/\Ptentm1Mro
\Trp53tm1Brn/\Trp53tm1Brn
involves: 129P2/OlaHsd * 129S4/SvJaeSor 		increased astrocytoma incidence J:229481
increased glioma incidence J:229481
increased oligodendroglioma incidence J:229481
\Gt(ROSA)26Sortm1Sor/\Gt(ROSA)26Sortm1Sor
\Ptentm1Mro/\Ptentm1Mro
\Trp53tm1Brn/\Trp53tm1Brn
involves: 129P2/OlaHsd * 129S4/SvJaeSor * C57BL/6 * FVB 		increased astrocytoma incidence J:204385
increased glioma incidence J:204385
increased oligodendroglioma incidence J:204385
\Gt(ROSA)26Sortm2(cre/ERT2)Brn/\Gt(ROSA)26Sor+
\Ptentm2Mak/\Ptentm2Mak
\Tg(RasE)290Biat/0
involves: 129P2/OlaHsd * C57BL/6 * DBA/2 		increased lung tumor incidence J:226601
increased pancreas tumor incidence J:226601
premature death J:226601
\Gt(ROSA)26Sortm2(H1/tetO-RNAi:Pdpk1)Mrl/\Gt(ROSA)26Sor+
\Ptentm1Hwu/\Ptentm1Hwu
\Tg(Pbsn-cre)4Prb/0
involves: 129S4/SvJae * C57BL/6 * DBA/2 		enlarged prostate gland anterior lobe J:170965
increased prostate gland tumor incidence J:170965
increased prostate gland weight J:170965
prostate gland hyperplasia J:170965
\Gt(ROSA)26Sortm2Thl/\Gt(ROSA)26Sor+
\Ptentm1Hwu/\Ptentm1Hwu
\Trp53tm1Thl/\Trp53tm1Thl
\Tyrc-Brd/\Tyrc-Brd
involves: 129/Sv * 129S4/SvJae * C57BL/6 		increased glioblastoma incidence J:172585
increased tumor growth/size J:172585
premature death J:172585
\Gt(ROSA)26Sortm2Thl/\Gt(ROSA)26Sor+
\Ptentm1Hwu/\Ptentm1Hwu
\Tyrc-Brd/\Tyrc-Brd
involves: 129/Sv * 129S4/SvJae * C57BL/6 		increased glioblastoma incidence J:172585
premature death J:172585
\Hrastm1Jaf/\Hrastm1Jaf
\Ptentm2.1Ppp/\Ptentm2.1Ppp
\Tg(TPO-cre)1Shk/0
involves: 129S1/Sv * 129S6/SvEvTac * FVB/NCr 		increased thyroid tumor incidence J:231492
\Hspa5tm1Alee/\Hspa5+
\Ptentm1Hwu/\Ptentm1Hwu
\Tg(Pbsn-cre)4Prb/?
involves: 129 * 129S4/SvJae * C57BL/6 * DBA/2 		increased prostate gland adenocarcinoma incidence J:142106
increased prostate intraepithelial neoplasia incidence J:142106
\Hspa5tm1Alee/\Hspa5tm1.1Alee
\Ptentm1Hwu/\Ptentm1Hwu
\Tg(Pbsn-cre)4Prb/?
involves: 129 * 129S4/SvJae * C57BL/6 * DBA/2 		normal neoplasm J:142106
\Hspa5tm1Alee/\Hspa5tm1Alee
\Ptentm1Hwu/\Ptentm1Hwu
\Tg(Pbsn-cre)4Prb/?
involves: 129 * 129S4/SvJae * C57BL/6 * DBA/2 		normal neoplasm J:142106
\Igs2tm1(CAG-Met)Zsu/\Igs2+
\Ptentm1Hwu/\Ptentm1Hwu
\Tg(Pbsn-cre)4Prb/0
involves: 129 * C57BL/6 * DBA/2 * FVB/N 		increased carcinoma incidence J:268934
increased metastatic potential J:268934
increased prostate gland adenocarcinoma incidence J:268934
increased prostate gland tumor incidence J:268934
increased prostate intraepithelial neoplasia incidence J:268934
\Kdrtm1Jrt/\Kdr+
\Ptentm1Hwu/\Ptentm1Hwu
\Twist2tm1.1(cre)Dor/\Twist2+
B6.129-Twist2tm1.1(cre)Dor Kdrtm1Jrt Ptentm1Hwu 		abnormal lung morphology J:192736
abnormal vasculogenesis J:192736
\Krastm4Tyj/\Kras+
\Ptentm1Hwu/\Pten+
\Tg(Pbsn-cre)4Prb/0
involves: 129S4/SvJae * C57BL/6 * DBA/2 		increased metastatic potential J:184935
increased prostate gland adenocarcinoma incidence J:184935
premature death J:184935
\Krastm4Tyj/\Kras+
\Ptentm1Hwu/\Pten+
\Tg(Pdx1-cre)89.1Dam/0
involves: 129S4/SvJae * BALB/c * C57BL/6 		increased pancreas tumor incidence J:164210
increased pancreatic ductal adenocarcinoma incidence J:164210
increased pancreatic intraepithelial neoplasia incidence J:164210
pancreatic acinar-to-ductal metaplasia J:164210
premature death J:164210
\Krastm4Tyj/\Kras+
\Ptentm1Hwu/\Pten+
\Tg(Upk2-cre)6Xrw/0
involves: 129S4/SvJae * FVB/N 		increased skin papilloma incidence J:174242
\Krastm4Tyj/\Kras+
\Ptentm1Hwu/\Pten+
\Tg(Gfap-cre)77.6Mvs/0
involves: 129S4/SvJae * BALB/c * C57BL/6NHsd 		increased classified tumor incidence J:154673
increased neurofibroma incidence J:154673
increased neurofibrosarcoma incidence J:154673
premature death J:154673
\Krastm4Tyj/\Kras+
\Ptentm1Hwu/\Ptentm1Hwu
involves: 129S4/SvJae 		increased ovary tumor incidence J:161953
\Krastm4Tyj/\Kras+
\Ptentm1Hwu/\Ptentm1Hwu
involves: 129S4/SvJae * C57BL/6J 		increased endometrial carcinoma incidence J:96296
increased metastatic potential J:96296
premature death J:96296
\Krastm4Tyj/\Kras+
\Ptentm1Hwu/\Ptentm1Hwu
\Scgb1a1tm1.1(cre)Fjd/\Scgb1a1+
involves: 129S1/Sv * 129S4/SvJae * 129X1/SvJ 		increased lung adenocarcinoma incidence J:131721
increased lung adenoma incidence J:131721
increased lung carcinoma incidence J:131721
increased lung tumor incidence J:131721
lung inflammation J:131721
premature death J:131721
tachypnea J:131721
weight loss J:131721
\Krastm4Tyj/\Kras+
\Ptentm1Hwu/\Ptentm1Hwu
\Tg(Pbsn-cre)4Prb/0
involves: 129S4/SvJae * C57BL/6 * DBA/2 		abnormal prostate gland morphology J:184935
increased metastatic potential J:184935
increased prostate gland adenocarcinoma incidence J:184935
premature death J:184935
\Krastm4Tyj/\Kras+
\Ptentm1Hwu/\Ptentm1Hwu
\Tg(Pdx1-cre)89.1Dam/0
involves: 129S4/SvJae * BALB/c * C57BL/6 * CBA 		abnormal exocrine pancreas morphology J:164210
edema J:164210
exocrine pancreas atrophy J:164210
increased pancreatic ductal adenocarcinoma incidence J:164210
increased pancreatic intraepithelial neoplasia incidence J:164210
pancreatic acinar-to-ductal metaplasia J:164210
postnatal lethality, complete penetrance J:164210
\Krastm4Tyj/\Kras+
\Ptentm1Hwu/\Ptentm1Hwu
\Tg(Scgb1a1-cre)1Tauc/0
involves: 129S4/SvJae * C57BL/6 		abnormal bronchiole morphology J:136369
abnormal bronchus morphology J:136369
\Krastm4Tyj/\Kras+
\Ptentm2Mak/\Pten+
\Speer6-ps1Tg(Alb-cre)21Mgn/\Speer6-ps1+
involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6 * DBA 		increased cholangiocarcinoma incidence J:254370
increased hepatocellular carcinoma incidence J:254370
increased liver tumor incidence J:254370
\Krastm4Tyj/\Kras+
\Ptentm2Mak/\Ptentm2Mak
\Speer6-ps1Tg(Alb-cre)21Mgn/\Speer6-ps1+
involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6 * DBA 		bile duct hyperplasia J:254370
distended abdomen J:254370
enlarged liver J:254370
hemorrhagic ascites J:254370
increased cholangiocarcinoma incidence J:254370
increased liver tumor incidence J:254370
jaundice J:254370
postnatal growth retardation J:254370
premature death J:254370
weight loss J:254370
\Krastm4Tyj/\Kras+
\Ptentm2.1Ppp/\Ptentm2.1Ppp
\Tg(TPO-cre)1Shk/0
129.Cg-Krastm4Tyj Tg(Tpo-cre)1Shk Ptentm2.1Ppp 		decreased circulating thyroid-stimulating hormone level J:147732
enlarged thyroid gland J:147732
increased metastatic potential J:147732
increased thyroid carcinoma incidence J:147732
increased thyroxine level J:147732
premature death J:147732
\Krastm4Tyj/\Kras+
\Krt19tm1(cre/ERT)Ggu/\Krt19+
\Ptentm2Mak/\Ptentm2Mak
involves: 129P2/OlaHsd * 129S4/SvJae * 129S6/SvEvTac 		abnormal colon morphology J:254370
abnormal cystic duct morphology J:254370
abnormal extrahepatic bile duct morphology J:254370
abnormal gallbladder morphology J:254370
abnormal liver morphology J:254370
bronchial epithelial hyperplasia J:254370
dilated gallbladder J:254370
increased pancreatic intraepithelial neoplasia incidence J:254370
lung inflammation J:254370
premature death J:254370
respiratory failure J:254370
stomach mucosa hyperplasia J:254370
\Leprdb/\Leprdb
\Ptentm1Hwu/\Ptentm1Hwu
\Tg(Ins2-cre)25Mgn/0
involves: 129S4/SvJae * C57BL/6 * C57BLKS/J * DBA 		abnormal pancreatic islet morphology J:170206
normal homeostasis/metabolism phenotype J:170206
increased body weight J:170206
increased insulin secretion J:170206
insulin resistance J:170206
\Mirc14tm1.1Flv/\Mirc14tm1.1Flv
\Ptentm1Hwu/\Ptentm1Hwu
\Tg(Cd4-cre)1Cwi/0
involves: 129S4/SvJae * C57BL/6 * C57BL/6N * DBA/2 * SJL 		normal immune system phenotype J:203157
\Mlst8tm1Lex/\Mlst8+
\Ptentm1Rps/\Pten+
involves: 129S1/Sv * 129S5/SvEvBrd * C57BL/6 		extended life span J:144810
\MtorGt(OST92090)Lex/\Mtor+
\Ptentm1Rps/\Pten+
involves: 129S1/Sv * 129S5/SvEvBrd * C57BL/6 		extended life span J:144810
\Nf1tm1Fcr/\Nf1+
\Ptentm1Hwu/\Ptentm1Hwu
\Tg(Mx1-cre)1Cgn/0
B6.Cg-Tg(Mx1-cre)1Cgn Nf1tm1Fcr Ptentm1Hwu 		abnormal bone marrow morphology J:232645
abnormal hematopoietic stem cell morphology J:232645
abnormal hemopoiesis J:232645
abnormal liver morphology J:232645
abnormal lung morphology J:232645
abnormal spleen morphology J:232645
anemia J:232645
decreased B cell number J:232645
decreased bone marrow cell number J:232645
decreased hemoglobin content J:232645
decreased lymphocyte cell number J:232645
decreased T cell number J:232645
enlarged liver J:232645
enlarged spleen J:232645
increased granulocyte number J:232645
increased leukocyte cell number J:232645
increased liver weight J:232645
increased macrophage cell number J:232645
increased monocyte cell number J:232645
increased spleen weight J:232645
increased T cell acute lymphoblastic leukemia incidence J:232645
increased tumor incidence J:232645
premature death J:232645
thrombocytosis J:232645
\Nf1tm1Par/\Nf1+
\Ptentm1Hwu/\Pten+
\Trp53tm1Tyj/\Trp53+
\Tg(GFAP-cre)25Mes/0
involves: 129S1/Sv * 129S2/SvPas * 129S4/SvJae * 129X1/SvJ * FVB/N 		ataxia J:134611
increased astrocytoma incidence J:134611
increased brain tumor incidence J:134611
increased startle reflex J:134611
premature death J:134611
seizures J:134611
unidirectional circling J:134611
\Nf1tm1Par/\Nf1+
\Ptentm1Hwu/\Pten+
\Trp53tm1Elee/\Trp53+
\Tg(GFAP-cre)25Mes/0
involves: 129S1/Sv * 129S4/SvJae * 129X1/SvJ * FVB/N 		ataxia J:134611
increased astrocytoma incidence J:134611
increased brain tumor incidence J:134611
increased startle reflex J:134611
premature death J:134611
seizures J:134611
unidirectional circling J:134611
\Nf1tm1Par/\Nf1+
\Ptentm1Hwu/\Pten+
\Tg(Gfap-cre)77.6Mvs/0
involves: 129S1/Sv * 129S4/SvJae * 129X1/SvJ * BALB/c * C57BL/6NHsd 		normal neoplasm J:154673
\Nkx3-1tm1Mms/\Nkx3-1+
\Ptentm1Rps/\Pten+
involves: 129S1/Sv * 129S1/SvImJ * C57BL/6J 		increased prostate gland tumor incidence J:75085
increased prostate intraepithelial neoplasia incidence J:75085
\Nkx3-1tm1Mms/\Nkx3-1tm1Mms
\Ptentm1Rps/\Pten+
involves: 129S1/Sv * 129S1/SvImJ * C57BL/6J 		increased prostate gland tumor incidence J:75085
increased prostate intraepithelial neoplasia incidence J:75085
\Pdpk1tm1Maka/\Pdpk1tm1Maka
\Ptentm1Hwu/\Ptentm1Hwu
\Tg(Zp3-cre)93Knw/0
involves: 129S4/SvJae * C57BL/6J 		normal reproductive system phenotype J:165798
\Pgrtm2(cre)Lyd/\Pgr+
\Ptentm1Hwu/\Ptentm1Hwu
\Trp53tm1Brn/\Trp53tm1Brn
involves: 129 * C57BL/6 		endometrium hyperplasia J:139053
enlarged uterus J:139053
increased endometrial carcinoma incidence J:139053
premature death J:139053
\Pik3catm1.1Waph/\Pik3ca+
\Ptentm1Hwu/\Ptentm1Hwu
involves: 129S1/Sv * 129S4/SvJae * BALB/c * C57BL/6 		abnormal diaphragm morphology J:184382
abnormal ovary morphology J:184382
abnormal ovary physiology J:184382
abnormal peritoneum morphology J:184382
hemorrhagic ascites J:184382
increased adenocarcinoma incidence J:184382
increased granulosa cell tumor incidence J:184382
increased ovary tumor incidence J:184382
ovary hemorrhage J:184382
premature death J:184382
\Pik3catm1Jjz/\Pik3catm1Jjz
\Pik3cbtm1Jjz/\Pik3cbtm1Jjz
\Ptentm1Hwu/\Ptentm1Hwu
\Tg(KRT14-cre)#Smr/0
FVB.Cg-Pik3catm1Jjz Pik3cbtm1Jjz Ptentm1Hwu Tg(KRT14-cre)#Smr 		normal integument phenotype J:199362
\Pik3catm1Jjz/\Pik3catm1Jjz
\Ptentm1Hwu/\Ptentm1Hwu
\Tg(KRT14-cre)#Smr/0
FVB.Cg-Pik3catm1Jjz Ptentm1Hwu Tg(KRT14-cre)#Smr 		increased skin hamartoma incidence J:199362
skin lesions J:199362
thick epidermis stratum basale J:199362
thick skin J:199362
\Pik3cbtm1Jjz/\Pik3cbtm1Jjz
\Ptentm1Hwu/\Ptentm1Hwu
\Tg(KRT14-cre)#Smr/0
FVB.Cg-Pik3cbtm1Jjz Ptentm1Hwu Tg(KRT14-cre)#Smr 		abnormal epidermis suprabasal layer morphology J:199362
increased skin hamartoma incidence J:199362
skin lesions J:199362
thick skin J:199362
\Pik3cdtm1Tnr/\Pik3cdtm1Tnr
\Ptentm2.1Ppp/\Ptentm2.1Ppp
\Cd19tm1(cre)Cgn/\Cd19+
involves: 129P2/OlaHsd * 129S1/Sv * 129S4/SvJae * C57BL/6 		abnormal class switch recombination J:130950
normal immune system phenotype J:130950
increased marginal zone B cell number J:130950
\Pik3cgtm1Pngr/\Pik3cgtm1Pngr
\Ptentm2Mak/\Ptentm2Mak
\Tg(Ckmm-cre)5Khn/0
involves: 129P2/OlaHsd * FVB 		cardiac hypertrophy J:79151
enlarged heart J:79151
increased cardiac muscle contractility J:79151
\Pkn3tm1.1Mrl/\Pkn3+
\Ptentm1Hwu/\Ptentm1Hwu
\Tg(Mx1-cre)1Cgn/0
involves: 129S4/SvJae * C57BL/6 * CBA/J 		enlarged spleen J:216983
enlarged thymus J:216983
extramedullary hematopoiesis J:216983
increased acute lymphoblastic leukemia incidence J:216983
increased hemolymphoid system tumor incidence J:216983
premature death J:216983
\Pkn3tm1.1Mrl/\Pkn3tm1.1Mrl
\Ptentm1Hwu/\Ptentm1Hwu
\Tg(CD2-icre)4Kio/0
involves: 129S4/SvJae * C57BL/6 * C57BL/10 * CBA/Ca 		normal endocrine/exocrine gland phenotype J:216983
\Pkn3tm1.1Mrl/\Pkn3tm1.1Mrl
\Ptentm1Hwu/\Ptentm1Hwu
\Tg(Mx1-cre)1Cgn/0
involves: 129S4/SvJae * C57BL/6 * CBA/J 		enlarged spleen J:216983
enlarged thymus J:216983
extramedullary hematopoiesis J:216983
increased acute lymphoblastic leukemia incidence J:216983
increased hemolymphoid system tumor incidence J:216983
premature death J:216983
\Prkar1atm1.2Lsk/\Prkar1a+
\Ptentm1.1Mwst/\Pten+
\Tg(TPO-cre)1Shk/0
involves: 129S1/Sv * 129X1/SvJ * FVB/NCr 		decreased survivor rate J:225245
normal neoplasm J:225245
\Prkar1atm1.2Lsk/\Prkar1atm1.2Lsk
\Ptentm1.1Mwst/\Ptentm1.1Mwst
\Tg(TPO-cre)1Shk/0
involves: 129S1/Sv * 129X1/SvJ * FVB/NCr 		decreased abdominal adipose tissue amount J:225245
decreased subcutaneous adipose tissue amount J:225245
enlarged thyroid gland J:225245
increased activity of thyroid gland J:225245
increased circulating thyroxine level J:225245
increased metastatic potential J:225245
increased thyroid carcinoma incidence J:225245
premature death J:225245
weight loss J:225245
\Ptentm1.1Hwu/\Pten+
\Tmprss2tm1.1(ERG)Sho/\Tmprss2tm1.1(ERG)Sho
involves: 129S4/SvJae * C57BL/6 * DBA/2 		increased prostate intraepithelial neoplasia incidence J:212219
\Ptentm1.1Hwu/\Pten+
\Tmprss2tm2.1(ETV1)Sho/\Tmprss2tm2.1(ETV1)Sho
involves: 129S4/SvJae * C57BL/6 * DBA/2 		increased prostate intraepithelial neoplasia incidence J:212219
\Ptentm1.1Mro/\Pten+
\Sdhbtm1.2Ics/\Sdhb+
involves: 129S2/SvPas * BALB/c * C57BL/6 		increased metastatic potential J:236514
increased pheochromocytoma incidence J:236514
\Ptentm1.1Mwst/\Ptentm1.1Mwst
\Tg(MMTVneu)202Mul/0
\Tg(S100a4-cre)1Gle/0
involves: FVB/N 		increased mammary adenocarcinoma incidence J:153747
increased mammary gland tumor incidence J:153747
\Ptentm1Hwu/\Pten+
\Tg(ARR2/Pbsn-FGF8)3Prb/0
\Tg(Pbsn-cre)4Prb/0
involves: 129S4/SvJae * BALB/c * C57BL/6 * DBA/2 		enlarged prostate gland J:106650
increased metastatic potential J:106650
increased prostate gland adenocarcinoma incidence J:106650
increased prostate intraepithelial neoplasia incidence J:106650
prostate gland epithelial hyperplasia J:106650
\Ptentm1Hwu/\Pten+
\Tmprss2tm2.1(ETV1)Sho/\Tmprss2tm2.1(ETV1)Sho
\Tg(Pbsn-cre)4Prb/0
involves: 129S4/SvJae * C57BL/6 * DBA/2 		increased prostate gland adenocarcinoma incidence J:212219
premature death J:212219
prostate gland cyst J:212219
\Ptentm1Hwu/\Ptentm1Hwu
\Cop1tm2.1Vmd/\Cop1tm2.1Vmd
\Tg(Pbsn-cre)4Prb/0
B6N.CgCop1tm2.1Vmd Ptentm1Hwu Tg(Pbsn-cre)4Prb 		increased prostate gland adenocarcinoma incidence J:172653
increased prostate intraepithelial neoplasia incidence J:172653
\Ptentm1Hwu/\Ptentm1Hwu
\Ptpn1tm1Bpk/\Ptpn1tm1Bpk
\Tg(Pbsn-cre)4Prb/0
involves: 129S4/SvJae * C57BL/6 * DBA/2 		increased prostate gland adenocarcinoma incidence J:231906
increased prostate intraepithelial neoplasia incidence J:231906
\Ptentm1Hwu/\Ptentm1Hwu
\Ptpn11tm1Gsf/\Ptpn11tm1Gsf
\Tg(Six3-cre)69Frty/0
involves: 129S1/Sv * 129S4/SvJae * 129X1/SvJ * C57BL/6 * DBA/2 		optic nerve atrophy J:174095
retina degeneration J:174095
retina ganglion cell degeneration J:174095
retina outer nuclear layer degeneration J:174095
thin retina ganglion layer J:174095
thin retina inner nuclear layer J:174095
thin retina outer nuclear layer J:174095
\Ptentm1Hwu/\Ptentm1Hwu
\Rictortm1.1Mgn/\Rictortm1.1Mgn
involves: 129S4/SvJae * 129S6/SvEvTac 		abnormal prostate gland duct morphology J:144810
abnormal prostate gland epithelium morphology J:144810
decreased tumor incidence J:144810
\Ptentm1Hwu/\Ptentm1Hwu
\Rictortm1.1Mgn/\Rictortm1.1Mgn
\Tg(Ins2-cre)25Mgn/0
involves: 129S4/SvJae * 129S6/SvEvTac * BALB/c * C57BL/6 * DBA 		abnormal glucose homeostasis J:170129
abnormal pancreatic beta cell morphology J:170129
decreased circulating insulin level J:170129
decreased pancreatic beta cell mass J:170129
hypoglycemia J:170129
postnatal growth retardation J:170129
\Ptentm1Hwu/\Ptentm1Hwu
\Rps6kb1tm1Gtho/\Rps6kb1tm1Gtho
\Tg(Mx1-cre)1Cgn/0
involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6 * CBA 		enlarged spleen J:169097
enlarged thymus J:169097
increased acute lymphoblastic leukemia incidence J:169097
premature death J:169097
\Ptentm1Hwu/\Ptentm1Hwu
\Smad4tm2.1Cxd/\Smad4tm2.1Cxd
\Tg(Alb1-cre)1Dlr/0
involves: 129S4/SvJae * 129S6/SvEvTac * FVB/N 		abnormal bile duct morphology J:111718
enlarged liver J:111718
hepatic steatosis J:111718
increased cholangiocarcinoma incidence J:111718
increased liver weight J:111718
premature death J:111718
\Ptentm1Hwu/\Ptentm1Hwu
\Tg(CAG-EGFP,-PAX8/PPARG)1Rkoe/0
\Tg(TPO-cre)1Shk/0
involves: 129S4/SvJae * FVB/NCr * FVB/NJ 		abnormal thymus physiology J:177181
abnormal thyroid gland morphology J:177181
enlarged thyroid gland J:177181
increased circulating thyroxine level J:177181
increased circulating triiodothyronine level J:177181
increased thyroid carcinoma incidence J:177181
\Ptentm1Hwu/\Ptentm1Hwu
\Tg(CAG-fat-1)1Jxk/0
\Tg(Pbsn-cre)4Prb/0
involves: 129S4/SvJae * BALB/c * C57BL/6 * DBA/2 		abnormal lipid homeostasis J:124208
decreased prostate gland weight J:124208
\Ptentm1Hwu/\Ptentm1Hwu
\Tg(CAG-MYC,-GFP*)#Rugg/0
\Tg(Pbsn-cre)4Prb/0
involves: 129S4/SvJae * C57BL/6 * C57BL/6J * DBA/2 		increased prostate gland adenocarcinoma incidence J:261540
increased prostate intraepithelial neoplasia incidence J:261540
premature death J:261540
\Ptentm1Hwu/\Ptentm1Hwu
\Tg(Pdx1-cre)89.1Dam/0
\Trp53tm1Tyj/\Trp53tm1Tyj
involves: 129S2/SvPas * 129S4/SvJae * C57BL/6 * CBA 		increased pancreatic acinar cell carcinoma incidence J:102226
increased pancreatic ductal adenocarcinoma incidence J:102226
\Ptentm1Hwu/\Ptentm1Hwu
\Tgfbr1tm1.1Karl/\Tgfbr1tm1.1Karl
\Tg(KRT14-cre/ERT)20Efu/0
involves: 129 * 129S4/SvJae * C57BL/6 * CD-1 * FVB/N 		abnormal anal canal morphology J:209026
increased oral papilloma incidence J:194652
increased organ/body region tumor incidence J:209026
increased papilloma incidence J:194652
increased squamous cell carcinoma incidence J:194652, J:209026
\Ptentm1Hwu/\Ptentm1Hwu
\Trp53tm1Brn/\Trp53tm1Brn
involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6 * FVB 		increased carcinoma incidence J:146760
increased urinary bladder carcinoma incidence J:146760
premature death J:146760
\Ptentm1Hwu/\Ptentm1Hwu
\Trp53tm2Tyj/\Trp53+
\Amhr2tm3(cre)Bhr/\Amhr2+
involves: 129P2/OlaHsd * 129S4/SvJae * 129S7/SvEvBrd 		ascites J:222579
increased granulosa cell tumor incidence J:222579
increased metastatic potential J:222579
increased ovarian carcinoma incidence J:222579
premature death J:222579
\Ptentm1Hwu/\Ptentm1Hwu
\Tsc1tm1Djk/\Tsc1tm1Djk
\Tg(Gdf9-icre)5092Coo/?
involves: 129S4/SvJae * C57BL/6J 		abnormal ovarian follicle morphology J:155357
\Ptentm1Hwu/\Ptentm1Hwu
\Vhltm1Jae/\Vhltm1Jae
\Tg(Cdh16-cre)91Igr/0
involves: 129S4/SvJae * BALB/c * C57BL/6J * ICR 		abnormal kidney cortex morphology J:137073
abnormal kidney epithelium morphology J:137073
abnormal kidney pelvis urothelium morphology J:137073
abnormal renal tubule epithelial cell primary cilium morphology J:137073
hydronephrosis J:137073
increased kidney cell proliferation J:137073
increased kidney weight J:137073
kidney cortex cyst J:137073
kidney cyst J:137073
kidney medulla cyst J:137073
normal neoplasm J:137073
\Ptentm1Hwu/\Ptentm1Hwu
\Vhltm1Jae/\Vhltm1Jae
\Tg(Cdh16-cre)91Igr/0
involves: 129S4/SvJae * ICR 		abnormal epididymis morphology J:137442
abnormal oviduct morphology J:137442
abnormal uterine cervix squamous epithelium morphology J:137442
endometrium hyperplasia J:137442
increased adenoma incidence J:137442
increased epididymal cystadenoma incidence J:137442
increased tumor incidence J:137442
\Ptentm1Mro/\Pten+
\Sdhbtm1.1Ics/\Sdhb+
\Tg(KLK3-cre)D4Trp/0
involves: 129S2/SvPas * FVB 		increased pheochromocytoma incidence J:236514
\Ptentm1Mro/\Ptentm1Mro
\Sdhbtm1.1Ics/\Sdhb+
\Tg(KLK3-cre)D4Trp/0
involves: 129S2/SvPas * FVB 		increased pheochromocytoma incidence J:236514
\Ptentm1Mro/\Ptentm1Mro
\Sdhbtm1.1Ics/\Sdhbtm1.2Ics
\Tg(KLK3-cre)D4Trp/0
involves: 129S2/SvPas * BALB/c * C57BL/6 * FVB 		increased pheochromocytoma incidence J:236514
\Ptentm1Mro/\Ptentm1Mro
\Tg(KRT14-cre)8Brn/0
\Trp53tm1Brn/\Trp53tm1Brn
involves: 129P2/OlaHsd * C57BL/6 * DBA/2 * DBA/2J * FVB/N 		increased carcinoma incidence J:144831
premature death J:144831
weakness J:144831
\Ptentm1Ppp/\Pten+
\Rac1tm1Tyb/\Rac1tm2Tyb
\Edil3Tg(Sox2-cre)1Amc/\Edil3+
involves: 129S/Sv * C3H * C57BL/6 * CBA 		abnormal apoptosis J:173526
abnormal embryo development J:173526
\Ptentm1Ppp/\Pten+
\Tg(Pbsn-TAg)15Tvd/0
involves: 129S1/Sv * C57BL/6 * DBA/2 		abnormal prostate gland physiology J:103408
increased prostate gland adenocarcinoma incidence J:103408
increased prostate gland tumor incidence J:103408
increased prostate intraepithelial neoplasia incidence J:103408
\Ptentm1Rdp/\Pten+
\Trp53tm1Brn/\Trp53tm1Brn
\Tg(GFAP-cre)25Mes/0
involves: 129P2/OlaHsd * 129S6/SvEvTac * C57BL/6 * FVB/N 		ataxia J:140704
increased astrocytoma incidence J:140704
increased glioblastoma incidence J:140704
increased glioma incidence J:140704
paralysis J:140704
seizures J:140704
\Ptentm1Rdp/\Ptentm1Rdp
\Smad4tm1Rdp/\Smad4tm1Rdp
\Trp53tm1Brn/\Trp53tm1Brn
\Tg(Pbsn-cre)4Prb/0
involves: 129 * C57BL/6 * DBA/2 		increased metastatic potential J:186105
increased prostate gland adenocarcinoma incidence J:186105
premature death J:186105
\Ptentm1Rdp/\Ptentm1Rdp
\Terttm1Rdp/\Tert+
\Trp53tm1Brn/\Trp53tm1Brn
\Tg(Pbsn-cre)4Prb/0
involves: 129P2/OlaHsd * 129S6/SvEvTac * C57BL/6 * DBA/2 		increased prostate gland adenocarcinoma incidence J:186105
increased prostate intraepithelial neoplasia incidence J:186105
premature death J:186105
\Ptentm1Rdp/\Ptentm1Rdp
\Terttm1Rdp/\Terttm1Rdp
\Trp53tm1Brn/\Trp53tm1Brn
\Tg(Pbsn-cre)4Prb/0
involves: 129P2/OlaHsd * 129S6/SvEvTac * C57BL/6 * DBA/2 		decreased telomere length J:186105
decreased tumor growth/size J:186105
increased prostate intraepithelial neoplasia incidence J:186105
\Ptentm1Rdp/\Ptentm1Rdp
\Terttm3Rdp/\Terttm3Rdp
\Trp53tm1Brn/\Trp53tm1Brn
\Tg(Pbsn-cre)4Prb/0
involves: 129P2/OlaHsd * 129S6/SvEvTac * C57BL/6 * DBA/2 		abnormal chromosome morphology J:186105
decreased tumor-free survival time J:186105
increased metastatic potential J:186105
increased prostate gland adenocarcinoma incidence J:186105
increased prostate intraepithelial neoplasia incidence J:186105
increased telomere length J:186105
\Ptentm1Rdp/\Ptentm1Rdp
\Trp53tm1Brn/\Trp53tm1Brn
\Tg(Pbsn-cre)4Prb/0
involves: 129P2/OlaHsd * 129S6/SvEvTac * C57BL/6 * DBA/2 		increased prostate gland adenocarcinoma incidence J:186105
increased prostate intraepithelial neoplasia incidence J:186105
premature death J:186105
\Ptentm1Rps/\Pten+
\Tg(Wnt1)1Hev/0
involves: 129S1/Sv * C57BL/6 * FVB/N * SJL 		increased adenocarcinoma incidence J:67497
increased mammary adenocarcinoma incidence J:67497
increased mammary gland ductal carcinoma incidence J:67497
increased metastatic potential J:67497
increased salivary adenocarcinoma incidence J:67497
\Ptentm1Rps/\Pten+
\Slc6a4tm1Kpl/\Slc6a4+
B6.129-Slc6a4tm1Kpl Ptentm1Rps 		abnormal social investigation J:144937
decreased prepulse inhibition J:144937
increased brain weight J:144937
megacephaly J:144937
reduced sensorimotor gating J:144937
\Ptentm1Rps/\Pten+
\Rptortm1Lex/\Rptor+
involves: 129S/SvEvBrd * 129S1/Sv * C57BL/6 		normal mortality/aging J:144810
\Ptentm1Rps/\Pten+
\RictorGt(RRR347)Byg/\Rictor+
involves: 129P2/OlaHsd * 129S1/Sv * BALB/c * C57BL/6 		decreased tumor incidence J:144810
extended life span J:144810
prostate gland hyperplasia J:144810
\Ptentm2.1Ppp/\Pten+
\Spry1tm1Jdli/\Spry1tm1.1Jdli
\Spry2tm1Mrt/\Spry2tm1.1Mrt
\Tg(Osr1-cre)4Mrt/0
involves: 129P2/OlaHsd * 129S1/Sv * 129X1/SvJ * FVB/N 		increased prostate gland tumor incidence J:192348
increased prostate intraepithelial neoplasia incidence J:192348
\Ptentm2.1Ppp/\Pten+
\Tg(Cnp-EGFR)10Nrat/0
\Tg(Dhh-cre)1Mejr/0
involves: 129S1/Sv * C57BL/6 * FVB/N * SJL 		abnormal nervous system morphology J:195067
abnormal sciatic nerve morphology J:195067
abnormal trigeminal nerve morphology J:195067
increased neurofibrosarcoma incidence J:195067
\Ptentm2.1Ppp/\Ptentm2.1Ppp
\Rb1tm2Brn/\Rb1tm2Brn
\Tg(Pbsn-cre)4Prb/0
involves: 129 * 129S1/Sv * 129S6/SvEvTac * C57BL/6 * DBA/2 		increased prostate intraepithelial neoplasia incidence J:307910
premature death J:307910
\Ptentm2.1Ppp/\Ptentm2.1Ppp
\Tg(CAG-Bgeo,-Spry2,-ALPP)1Mrt/0
\Tg(Osr1-cre)4Mrt/0
involves: 129P2/OlaHsd * 129S1/Sv * FVB/N 		increased prostate intraepithelial neoplasia incidence J:192348
\Ptentm2.1Ppp/\Ptentm2.1Ppp
\Tg(Cnp-EGFR)10Nrat/0
\Tg(Dhh-cre)1Mejr/0
involves: 129S1/Sv * C57BL/6 * FVB/N * SJL 		abnormal nervous system morphology J:195067
abnormal sciatic nerve morphology J:195067
abnormal trigeminal nerve morphology J:195067
enlarged dorsal root ganglion J:195067
increased neurofibrosarcoma incidence J:195067
premature death J:195067
\Ptentm2.1Ppp/\Ptentm2.1Ppp
\Tg(GFAP-TAg121)1Tvd/0
involves: 129S1/Sv * C57BL/6 * C57BL/6J * DBA/2 * FVB/N 		abnormal astrocyte apoptosis J:99385
abnormal brain vasculature morphology J:99385
increased angiogenesis J:99385
increased astrocytoma incidence J:99385
\Ptentm2.1Ppp/\Ptentm2.1Ppp
\Trp53tm1Brn/\Trp53tm1Brn
\Tg(TPO-cre)1Shk/0
129.Cg-Tg(TPO-cre)1Shk Trp53tm1Brn Ptentm2.1Ppp 		decreased thyroid-stimulating hormone level J:211100
enlarged thyroid gland J:211100
increased metastatic potential J:211100
increased thyroid carcinoma incidence J:211100
premature death J:211100
\Ptentm2.1Ppp/\Ptentm2.1Ppp
\Trp53tm1Thl/\Trp53tm1Thl
\Tg(Pbsn-cre)4Prb/0
involves: 129S1/Sv * C57BL/6 * DBA/2 		increased carcinoma incidence J:100683
increased prostate gland tumor incidence J:100683
kidney failure J:100683
premature death J:100683
urinary bladder obstruction J:100683
\Ptentm2Mak/\Ptentm2Mak
\Smad4tm2.1Cxd/\Smad4tm2.1Cxd
\Tg(KRT5-cre)1Xya/0
involves: 129P2/OlaHsd * 129S6/SvEvTac 		abnormal hair follicle regression J:101602
alopecia J:101602
decreased tumor latency J:101602
epithelioid cyst J:101602
increased carcinoma incidence J:101602
increased hair follicle cell proliferation J:101602
increased keratinocyte proliferation J:101602
increased skin papilloma incidence J:101602
increased skin tumor incidence J:101602
increased stomach tumor incidence J:101602
premature death J:101602
thick epidermis J:101602
thick hair follicle outer root sheath J:101602
\Ptentm2Mak/\Ptentm2Mak
\Stk11tm1Keis/\Stk11tm1Keis
\Tg(Cyp1a1-cre/ERT)1Dwi/0
involves: 129P2/OlaHsd * C57BL/6 * C57BL/6J * CBA 		abnormal urinary bladder mucosa morphology J:169565
abnormal urinary bladder urothelium morphology J:169565
enlarged urinary bladder J:169565
increased urinary bladder carcinoma incidence J:169565
premature death J:169565
urinary bladder obstruction J:169565
\Ptentm2Mak/\Ptentm2Mak
\Tg(Ckmm-cre)5Khn/0
\Tg(Myh6-Pik3ca)1Siz/0
involves: 129P2/OlaHsd * FVB 		decreased cardiac muscle contractility J:79151
small heart J:79151
\Ptentm2Mak/\Ptentm2Mak
\Tg(GFAP-cre/Esr1*,-lacZ)ASbk/0
\Trp53tm1Brn/\Trp53tm1Brn
involves: 129P2/OlaHsd * FVB/NJ 		increased glioblastoma incidence J:290447
premature death J:290447
\Ptentm2Mak/\Ptentm2Mak
\Trp53tm1Brn/\Trp53tm1Brn
\Tg(MMTV-cre)#Tfln/0
involves: 129P2/OlaHsd * C57BL/6 * FVB/N 		increased mammary adenocarcinoma incidence J:224955
increased mammary gland tumor incidence J:224955
increased myoepithelioma incidence J:224955
increased spindle cell carcinoma incidence J:224955
\Ptentm2Mak/\Ptentm2Mak
\Trp53tm1Brn/\Trp53tm1Brn
\Tg(Nes-cre/ERT2,-ALPP)1Sbk/0
involves: 129P2/OlaHsd 		abnormal cerebellum morphology J:237990
increased glioma incidence J:237990
increased medulloblastoma incidence J:237990
\Ptentm2Mak/\Ptentm2Mak
\Trp53tm1Brn/\Trp53tm1Brn
\Tg(Wap-cre)11738Mam/0
involves: 129P2/OlaHsd * C57BL/6 * FVB/N * SJL 		increased mammary adenocarcinoma incidence J:224955
increased mammary gland tumor incidence J:224955
increased myoepithelioma incidence J:224955
increased spindle cell carcinoma incidence J:224955
\Ube2otm1.1(KOMP)Mbp/\Ube2otm1.1(KOMP)Mbp
\Ptentm1Ppp/\Ptentm1Ppp
involves: 129S1/Sv * C57BL/6 * C57BL/6N * FVB/N 		increased lymphoma incidence J:239679
Contributing Projects:
Mouse Genome Database (MGD), Gene Expression Database (GXD), Mouse Models of Human Cancer database (MMHCdb) (formerly Mouse Tumor Biology (MTB)), Gene Ontology (GO)
Citing These Resources
Funding Information
Warranty Disclaimer, Privacy Notice, Licensing, & Copyright
Send questions and comments to User Support. 		last database update
03/25/2025
MGI 6.24 		The Jackson Laboratory